The potential relevance of chromosome 7q21-22 in susceptibility to multiple sclerosis (MS) has been highlighted in genomewide linkage screens as well as in association studies of 7q-specific polymorphic microsatellites. Especially, recent, independently performed studies have provided evidence for significant association of the markers D7S554 and D7S3126 with MS in Sardinian, Northern Irish and Spanish-American cohorts. The gene most closely located to these markers is the neuropeptide preprotachykinin-1 (TAC1) gene. Both its position and the array of biological functions exerted by its expression products make it a logical primary choice for further scrutiny as the putative chromosome 7q21-22 MS susceptibility gene. We report identification of eight polymorphisms in this gene by means of a sequencing approach. A Northern Irish case-control was typed for six of these polymorphisms. One of these, an intron 1 single-nucleotide polymorphism (SNP), showed significant association with MS (P ¼ 0.009). Two-marker haplotypes composed of allelic combinations of TAC1 promoter-intron 1 SNPs were highly significantly associated with MS and more so with the relapsing-remitting form of this disease. While independent reproduction of these data in other data sets is indicated, our work is suggestive for a role of the TAC1 gene in MS.
Introduction
Multiple sclerosis (MS) is a chronic autoimmune-type disorder of the central nervous system (CNS) characterized by inflammation, demyelination and axonal degeneration. 1 It is now widely accepted that the disease surfaces in genetically susceptible individuals who have been exposed to an as yet elusive causative agent or group of agents. 2 A large body of studies is suggestive for a polygenic model, in which several genes each contribute a small to moderate effect to the overall risk for contracting MS. Moreover, evidence is mounting for the existence of genes that do not affect susceptibility per se but appear to influence disease variables. 3, 4 We have recently presented evidence for an MS susceptibility locus lying in the q21-22 region of chromosome 7. 5 In two different patient cohorts, a trio family-based set from Sardinia and a case-control set from Northern Ireland, we found evidence for significant allelic association of the marker D7S554 with MS. 5 In a second stage, we analysed five microsatellite markers located in a 4 Mb 7q21-22 interval in the Sardinian set and found evidence for highly significant transmission disequilibrium of one of these, that is, D7S3126.
5
Interestingly, Villoslada et al 6 independently reported allelic association of D7S3126 with MS in a group of Spanish and American trio MS families. Taken together, these findings reinforce previous indications for a role of chromosome 7q21-22 in susceptibility to MS, which initially arose from the primary and updated full genome linkage screens performed on American families. 7, 8 Preprotachykinin-1 (TAC1) is the gene most closely located to the two chromosome 7q21-22 markers emerging from the combined Sardinian, 5 Northern Irish 5 and Spanish-American 6 data sets. The order and spacing from centromer to telomer is as follows: D7S3126 -41 kb -D7S554 -36 kb -TAC1. The next most closely located known gene in telomeric direction is asparagine synthetase (ASNS) at a distance of 156 kb from D7S554. Moving towards the centromer, the first known gene, DC11, is separated by 4460 kb from D7S3126. The range over which linkage disequilibrium (LD) around D7S554 and D7S3126 extends was calculated in the Sardinian families in which it was estimated to be 460 kb for D 0 40.35 (Po10
À7
). 5 In view of these positional considerations, as well as of current notions on LD in the human genome, 9 we decided that TAC1 would constitute a logical primary choice for further scrutiny as the putative chromosome 7q21-22 MS susceptibility gene. In the present manuscript, we have identified a series of single-nucleotide polymorphisms (SNPs) and two novel repeat elements in the TAC1 gene by direct sequencing of genomic DNA, and have analysed individual and two-marker haplotype association of six of these polymorphisms with MS using a Northern Irish case-control. The case-control data include the earlier Northern Ireland samples used to derive the association with D7S554. 5 Although a casecontrol study design may run an inherent risk of yielding false positive effects due to population stratification, it may, however, be particularly appropriate for a population such as the Northern Irish, known to exhibit a pronounced ethnic and genetic homogeneity (499% Caucasian at the 2001 Census; http://www.nisra. gov.uk/census/Census2001Output).
We report identification of a haplotype extending over the promoter and intron 1 of TAC1 that is highly significantly associated with MS, and more so with the relapsing-remitting (RR) form of this disease.
Results and discussion
We adopted a sequencing strategy for uncovering of polymorphic positions in the TAC1 gene that focused on information-bearing portions of the TAC1 gene, including the complete proximal promoter region, seven exons, B200-bp intron boundaries of the larger introns as well as the small first and third introns in their entirety ( Figure 1 ). Sequencing of all fragments was performed in 10 MS patients and 10 healthy control subjects. Comparison of the sequences using Sequencher software revealed the presence of eight polymorphisms, five of which appeared not to have been described hitherto, that is, (i) an intron 3 C/G SNP (position 96975203), (ii) an intron 5 G/T SNP (position 96976720), (iii) an exon 7 G/ A SNP (position 96981071) and (iv and v) two repeat elements in the 3 0 untranslated region, that is, GT repeat (position 96981418) and a biallelic GCAC repeat element (position 96981525). The three known polymorphisms we confirmed in this screen were the promoter G/C SNP rs7793277 (position 96971316), the intron 1 A/G SNP rs2072100 (position 96973515) and the intron 6 T/C SNP rs1229434 (position 96977573). In total, 407 Northern Irish MS patients, 305 of whom suffered from the RR form of the disease and 102 from the primaryprogressive form (PP), in addition to 165 Northern Irish control subjects were typed for a selection of five of these polymorphisms. Likewise, all individuals were genotyped for an A/G SNP (rs1510303) located 3887 bp downstream from exon 7 ( Figure 1 ). General clinical and demographic characteristics of this patient population have been described previously. 5 Primers and probes used for genotyping by fluorescence-polarization single-base extension (FP-SBE) 10 or fragment analysis are represented in Table 1 .
The genotypes of the six polymorphisms are shown in Table 2 for healthy controls, the unstratified MS group, and RR and PP clinical subgroups. Stratification of the clinical forms (RR and PP) was carried out on an exploratory basis, as there is currently no firm scientific basis for a genetic basis of this clinical divergence. Two polymorphisms showed weak deviations of HardyWeinberg (HW) equilibrium in the PP MS subgroup (PZ0.013), while the intron 3 SNP was in HW disequilibrium in all groups, including the controls (Table 2 ). To ascertain that this was not due to incorrect genotype calling with the FP-SBE approach, we retyped this SNP using an in-house designed Taqman s assay that, however, yielded identical results ( Table 1 ). The basis of this deviation from HW equilibrium is not clear and further genetic analysis will be necessary to ascertain if this polymorphism is an important marker in relation to TAC1 or a population-dependant polymorphism which within our population deviates from HW equilibrium, reflected by an excess of homozygotes for the C allele. It is worth noting that previous studies have also identified SNPs on chromosome 7q21-22 11 and in close proximity to this region, which were reported to occur in HW disequilibrium. 12 Retrospective power calculations were performed, based on comparison of minor allele frequencies in cases and controls, the resulting w 2 test for 2 Â 2 tables having similar power asymptotically to the w 2 test for trend that was used in this study (Table 2) when there is HW equilibrium. 13 For comparison of the unstratified MS case group against healthy controls, the power to detect an allele-wise odds ratio of 2 at the 5% significance level exceeded 85% for all but the intron 3 SNP whose lower minor allele frequency meant that power was only 70%. For comparison of the RR MS subgroup vs controls power was slightly less, but for the PP MS subgroup Figure 1 Sequencing strategy to uncover polymorphic positions in the TAC1 gene. The TAC1 nucleotide sequence and the surrounding region were obtained from Genbank accession number AC004104. The structure of TAC1 is represented with indication of exon sequences (roman numbers) and 5 0 and 3 0 UTR (light grey shaded areas). Direct cycle sequencing was used to fully sequence the regions indicated with horizontal arrows in 20 individuals. Briefly, the regions of interest were amplified using PCR, and overlapping bidirectional up-and downstream cycle sequencing reactions were performed using BigDye v3.1 (Applied Biosystems; Foster City, CA, USA). Sequence readouts were analysed using Sequencing Analysis v3.7 (Applied Biosystems; Foster City, CA, USA), and compared for polymorphisms using Sequencher v4.0.5 (Gene Codes Corp.; MI, USA). All primers and conditions used in amplification and sequencing reactions are available from the authors upon request. The six polymorphic positions indicated were selected for genotyping in the complete Northern Irish case-control. SNPs 1 and 3 were typed by means of fluorescence polarization -single-base extension (FP-SBE) 10 on an Analystt AD (Molecular Devices; Sunnyvale, CA, USA) using the primers and probes given in Table 1 . SNPs 2, 4 and 6 were genotyped using Taqman s predesigned SNP genotyping assays (assay IDs C2560484_1, C2560482_10 and C11242244_10, respectively) obtained from Applied Biosystems (Foster City; USA) by means of a DNA Engine Opticon s 2 Continuous Fluorescence Detection System (MJ Research; Waltham, MA, USA). Polymorphism 5 is a biallelic repeat element that was analysed by fragment analysis (for primer sequences, see Table 1 ) using electrophoresis through POP6-filled capillaries on a Prism s 3100 Genetic Analyzer (Applied Biosystems). A small number of samples genotyped by any of the three detection methods outlined above was resequenced to ensure correct allele calling.
Preprotachykinin-1 and susceptibility to MS S Cunningham et al against controls it decreased to between 70 and 80% for all loci except the 3 0 UTR RP (61%) and the intron 3 SNP (46%).
P-values for single markers were calculated using a w 2 test for trend with 1 df, which allows the HW assumption to be relaxed provided that genotype odds ratios adhere to a multiplicative model (Table 2 ). 14 Significant associations were found for rs7793277, rs2072100 and rs1510303 in either one or two of these groups. rs2072100 was the only marker retaining significant association with MS both in the unstratified analysis and in the analysis of RR MS patients with Bonferroni correction for the number of subgroups examined (Table 2) . Stratification according to HLA status was also performed. This analysis revealed P-values were calculated for comparison of genotype distribution between each of the three MS groups and healthy controls, applying a w 2 test for trend, which allows for the Hardy-Weinberg (HW) equilibrium assumption to be relaxed.
Genotype distributions that showed significant deviations (Po0.05) from HW equilibrium have been indicated by italics.
Preprotachykinin-1 and susceptibility to MS S Cunningham et al that none of the associations found in the unstratified group segregated with HLA-DRB1*15 status, and neither did new HLA-restricted associations arise (not shown).
To exemplify this, the association with rs2072100, which was the strongest in the unstratified MS group, was equally present in DRB*15 þ and DRB*15À patients compared to DRB1*15 þ and DRB1*15À controls (P ¼ 0.01 and P ¼ 0.04), respectively. Using the Arlequin software likelihood ratio, tests for pairs of markers in LD were performed. 15 Using genotype data from both cases and controls, Lewontin's D 016 was calculated with the STATA package (http://www.stata.com) by means of the pairwise linkage disequilibrium ado file PWLD (http:// www-gene.cimr.cam.ac.uk/clayton/software/). All markers were found to be in at least partial LD (0.4rD 0 r0.8), and were thus not considered to be independent. Since LD with a disease locus may be stronger for haplotypes than for single alleles, 17 twomarker haplotype frequency estimates were obtained by means of an expectation-maximization (EM) algorithm, and two-marker P-values for comparison of haplotype frequencies between cases and controls were obtained by a permutation test using the Fast-EHPlus software program. 18 The results of this analysis are shown in Figure 2 . Most strikingly, a P-value of 0.0003 was found for association with MS of two-marker haplotypes composed of allelic combinations of the TAC1 promoter and intron 1 SNPs (rs7793277 and rs2072100). Analysis of the clinical subgroups showed that the significance of this association was more pronounced in the RR MS (P ¼ 0.00007) than in the PP MS subgroup (P ¼ 0.14). The stronger association with the RR form of MS could reflect a functional effect unique to this disease course, although it is of note to recall that the B3-fold smaller sample size of the PP MS subgroup may evoke a lower power for association detection in this group. Odds ratios (OR) were calculated using the Thesias software program that takes into account uncertainties associated with haplotype frequency estimates. 19 The most strongly associated haplotype was rs7793277*C -rs2072100*G, yielding an odds ratio (OR; calculated for CG vs the most common haplotype GG) of 3.2 (95% CI 1.2-8.7) for unstratified MS, Replication of our findings in independent data sets will be crucial in order to establish their general relevance for MS. The effects of polymorphisms on Figure 2 Association of single markers and two-marker haplotypes in TAC1 with MS. Plots represent uncorrected P-values for differences in either genotype counts of individual markers (thin lines) or estimated haplotype frequencies for pairs of adjacent markers (bold lines) between MS patients and controls. MS patients were unstratified (a) or stratified according to disease course; that is, RR (b) or PP (c). P-values for single markers were calculated using a w 2 test for trend, which allows the HW assumption to be relaxed.
14 Maximum likelihood estimates of haplotype frequencies were calculated with an expectation-maximization (EM) algorithm implemented in the Arlequin v2.00 software (http://anthro.unige.ch/arlequin) 15 and P-values were calculated by means of the Fast-EHPlus program, 18 which uses a likelihood-ratio test statistic but assesses its significance with reference to its permutation distribution obtained from random relabellings of the cases and controls.
Preprotachykinin-1 and susceptibility to MS S Cunningham et al transcription regulation or splicing of TAC1 gene transcripts are not documented. An increasing body of literature attributes a functional role to tachykinins in CNS inflammation and processes occurring at the neuroimmune interface that may further underscore the potential relevance of our genetic findings. The TAC1 gene is transcribed into four known isoforms of mRNA that are the result of alternative splicing of the primary transcript, with each of these isoforms generating partially overlapping sets of neuropeptides including substance P (SP), neurokinin A, neuropeptide K and neuropeptide g. 20 Of these, SP, in particular, has received some attention regarding a potential role in MS. In the CNS, both nerve fibres and astrocytes are common sources of SP. 21 SPimmunoreactive astrocytes are found in MS plaques. 22 Astrocytes also express the high-affinity SP NK-1 receptor. 23 MS plaques tend to form around veins innervated by unmyelinated SP-containing fibres, and SP induces the proinflammatory cytokine interleukin-1 (IL-1) by microglia. 24 Other proinflammatory cytokines induced in neuroglial cells by SP and known to be associated with CNS inflammation include tumour necrosis factor-a (TNF-a), IL-6 and IL-8. 23, [25] [26] [27] In the presence of IFN-g and TNF-a, SP induces activation, and increases permeability, of the vascular component of the blood-brain barrier. 28 In endothelial cells, SP induces expression of the cell adhesion molecules ICAM-1 and VCAM-1. 29 When injected in the brainstem of experimental rats, SP strongly increased MHC class II upregulation on parenchymal microglial cells by IFN-g. 30 The brainstem is a common site of damage in MS. 30 Taken together, these data indicate that local SP directly contributes to activation of the normally quiescent CNS immune system. In view of these and our findings, as well as of the availability of effective SP agonists and antagonists with proven therapeutic value, 31 the TAC1 gene is worthy of further scrutiny in MS.
